Tevogen (TVGN) Cash from Operations (2022 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Cash from Operations came in at 2733769.0 in Q1 2026, up 17.36% YoY from 2329378.8 in Q1 2025, and down 25.33% on a QoQ basis from 2181267.0 in Q4 2025.
Tevogen (TVGN) Cash from Operations (2022 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 5 years of Cash from Operations data on file, last reported at 2733769.0 in Q1 2026.
- Quarterly Cash from Operations rose 17.36% year-over-year to 2733769.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11754283.0 (up 10.57% YoY) and the FY2025 annual result came in at 12328577.0, down 2.75% from the prior year.
- Cash from Operations declined to 2733769.0 in Q1 2026, from 2181267.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 13861.0 in Q4 2022 to a low of 3804709.0 in Q3 2024.
- A 5-year average of 2085152.29 and a median of 2181267.0 in 2025 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations plunged 14159.23% — and 2025, when it advanced 28.43%.
- Tracing TVGN's Cash from Operations over 5 years: stood at 13861.0 in 2022, then sank by 14159.23% to 1976472.0 in 2023, then plunged by 54.2% to 3047686.0 in 2024, then gained by 28.43% to 2181267.0 in 2025, then retreated by 25.33% to 2733769.0 in 2026.
- The last three Cash from Operations figures came in at 2733769.0 (Q1 2026), 2181267.0 (Q4 2025), and 3649544.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Tevogen | 25.62 Mn | 25.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.73 Mn |
| Mar 31, 2026 | -2.73 Mn |
| Dec 31, 2025 | -2.18 Mn |
| Dec 31, 2025 | -2.18 Mn |
| Sep 30, 2025 | -3.65 Mn |
| Sep 30, 2025 | -3.65 Mn |
| Jun 30, 2025 | -3.19 Mn |
| Jun 30, 2025 | -3.19 Mn |
| Mar 31, 2025 | -3.31 Mn |
| Mar 31, 2025 | -3.31 Mn |
| Dec 31, 2024 | -3.05 Mn |
| Dec 31, 2024 | -3.05 Mn |
| Sep 30, 2024 | -3.80 Mn |
| Sep 30, 2024 | -3.80 Mn |
| Jun 30, 2024 | -2.98 Mn |
| Jun 30, 2024 | -2.98 Mn |
| Mar 31, 2024 | -2.16 Mn |
| Mar 31, 2024 | -2.16 Mn |
| Dec 31, 2023 | -1.98 Mn |
| Dec 31, 2023 | -1.98 Mn |